Sustained Resolution of Nail Psoriasis Through 5 Years with Ixekizumab: A Post-Hoc analysis from UNCOVER-3

Alexander Egeberg, Lars Erik Kristensen, Ronald Vender, Shirin Zaheri, Celine El Baou, Gaia Gallo, Elisabeth Riedl, Christopher Schuster


Nail psoriasis is a chronic, difficult-to-treat condition affecting almost half of patients with psoriasis. It is associated with considerable social stigma and impairment of patients' quality of life. The aim of this study was to assess improvements in objective measures of nail psoriasis among patients from the long-term extension of the UNCOVER-3 study who received the interleukin-17A inhibitor ixekizumab and had either any degree of nail psoriasis (Nail Psoriasis Severity Index (NAPSI) >=1) or significant nail psoriasis (fingernail NAPSI ≥ 16 and ≥ 4 fingernails involved) at baseline. Efficacy outcomes reported through week 264 included the mean percentage improvements from baseline in NAPSI score and the proportion of patients achieving nail psoriasis resolution (NAPSI=0). In UNCOVER-3, 56.9% (219/385) of patients had nail psoriasis at baseline; of those, 61.2% (134/219) had significant nail psoriasis. At week 60, a total of 66.9% and 59.1% of patients with baseline nail psoriasis and significant baseline nail psoriasis, respectively, reported complete clearance of nail psoriasis, an effect which was sustained through week 264. This analysis demonstrates that continuous treatment with ixekizumab in adult patients with moderate-to-severe-psoriasis through 264 weeks was associated with improvements and clearance of fingernail psoriasis, irrespective of the severity of nail psoriasis at baseline.

Original languageEnglish
Article numberadv00787
JournalActa Dermato-Venereologica
Pages (from-to)adv00787
Publication statusPublished - 10 Oct 2022


  • Adult
  • Antibodies, Monoclonal, Humanized
  • Double-Blind Method
  • Humans
  • Interleukin-17
  • Nail Diseases/diagnosis
  • Psoriasis/complications
  • Quality of Life
  • Severity of Illness Index
  • Treatment Outcome


Dive into the research topics of 'Sustained Resolution of Nail Psoriasis Through 5 Years with Ixekizumab: A Post-Hoc analysis from UNCOVER-3'. Together they form a unique fingerprint.

Cite this